Welcome to our dedicated page for AdvanSix SEC filings (Ticker: ASIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdvanSix Inc. filings document an integrated chemistry issuer with common stock traded on the NYSE under ASIX. Its 8-K reports furnish operating results for Nylon Solutions, Plant Nutrients and Chemical Intermediates, cash dividends on common stock, executive and director appointments, committee assignments, and amendments to its senior secured revolving credit facility.
Proxy materials disclose board composition, independence, committee structure, executive compensation, equity awards and shareholder voting matters. The filing record also covers capital structure, financial obligations and governance practices tied to AdvanSix's vertically integrated manufacturing assets, raw-material exposure, plant operations and end markets for nylon, fertilizers and chemical intermediates.
AdvanSix Inc. entered into a new senior secured credit agreement with Citizens Bank providing a $275 million Revolving Credit Facility and a $150 million Term Facility, both maturing on August 14, 2031. The revolver includes sublimits of $40 million for letters of credit and $40 million for swing line loans.
Term loans amortize quarterly at 2.50% per year in the first year, 5.00% in years two through four, and 7.50% in year five, with the balance due at maturity. Borrowings bear interest at a base rate plus 0.50%–1.50% or Term SOFR plus 1.50%–2.50%, depending on the Consolidated Leverage Ratio, and unused revolver commitments carry a 0.20%–0.40% fee. At closing, AdvanSix drew $145 million on the revolver and $150 million on the term loan and held about $17 million of cash, using proceeds to refinance its prior facility and for general corporate purposes. The agreement is secured by substantially all tangible and intangible assets and includes financial covenants requiring a maximum 3.75x Consolidated Leverage Ratio and minimum 3.00x Consolidated Interest Coverage Ratio; noncompliance could result in accelerated repayment.
American Century Investment Management, Inc., together with American Century Companies, Inc. and the Stowers Institute for Medical Research, reports beneficial ownership of AdvanSix Inc. common stock. The group holds 1,363,346 shares, representing 5.1% of the outstanding common stock as of June 30, 2026.
The reporting persons have sole voting and sole dispositive power over the 1,363,346 shares, with no shared voting or dispositive power. Various investment company and institutional accounts advised by American Century Investment Management, Inc. have rights to dividends and sale proceeds, but no single client holds more than 5% of the class.
AdvanSix reported Q2 2026 sales of $421,284 thousand, up 2.7% year over year, but net income fell to $3,248 thousand. For the first half, sales reached $825,468 thousand while the company recorded a net loss of $(12,298) thousand and gross margin compressed to 4.2% from 14.2%.
Cost of goods sold rose 17.0% in the first half, driven by higher benzene, sulfur and propylene prices, increased plant and utility costs, winter-storm expenses and the absence of $26 million of insurance proceeds recognized a year earlier. Adjusted EBITDA declined to $36,644 thousand from $107,301 thousand, and Adjusted EBITDA Margin fell to 4.4% from 13.6%.
Operating cash flow turned negative at $(5,294) thousand versus $32,553 thousand a year ago, as AdvanSix funded $56,650 thousand of capital expenditures and increased revolver borrowings to $275,000 thousand, leaving approximately $224 million of availability and $7,217 thousand of cash. The company maintained a $0.16 per‑share quarterly dividend and has about $62.0 million of remaining share‑repurchase authorization, with repurchases currently paused. A goodwill impairment test was triggered by a sustained market‑capitalization decline, but no impairment was recorded.
AdvanSix reported second quarter 2026 sales of $421 million, up 3% year-over-year, driven by 18% favorable pricing that offset a 15% volume decline, mainly in Plant Nutrients. Net income fell to about $3.2 million, down 90% from the prior-year period, with diluted EPS at $0.12 versus $1.15. Adjusted diluted EPS was $0.19 compared with $1.24, and Adjusted EBITDA declined to $31.9 million, a 43% drop, reducing Adjusted EBITDA margin to 7.6% from 13.6%. Free cash flow was negative $10.7 million.
By product line, 2Q 2026 sales were $100.2 million in Nylon (up 26%), $62.6 million in Caprolactam (down 6%), $131.4 million in Plant Nutrients (down 16%), and $127.0 million in Chemical Intermediates (up 18%). For the first half of 2026, the company recorded a net loss of $12.3 million and negative operating cash flow of $5.3 million. The board declared a quarterly cash dividend of $0.16 per share, payable September 1, 2026 to shareholders of record on August 18, 2026. Management expects 2026 capital expenditures of $75–$95 million versus $116 million in 2025 and estimates the 2026 pre-tax income impact of plant turnarounds at about $17 million, below $25 million in 2025, and projects sequential cash flow improvement in the second half of 2026.
Dimensional Fund Advisors reports beneficial ownership of 1,407,349 shares of AdvanSix Inc. common stock, representing 5.2% of the class. The firm has sole voting power over 1,380,649 shares and sole dispositive power over 1,407,349 shares, with no shared voting or dispositive power.
The shares are owned by various funds and accounts advised or sub-advised by Dimensional and its subsidiaries. Because its role is to provide investment and voting discretion to these funds, Dimensional may be deemed a beneficial owner under Section 13(d) but expressly disclaims beneficial ownership. No single underlying fund’s interest exceeds 5% of the AdvanSix common stock.
AdvanSix Inc. director Patrick Williams received a grant of deferred stock units tied to the company’s common stock. He was allocated 660 units on June 30, 2026 at a reference value of $19.88 per unit under the AdvanSix Inc. Deferred Compensation Plan.
Each deferred stock unit represents the economic equivalent of one share of common stock and will be paid out in actual shares upon distribution. Following this compensation-related award, Williams directly holds 43,434 shares of AdvanSix common stock, indicating a routine, non–open-market acquisition.
AdvanSix Inc. director Jeffrey J. Bird received an equity grant of 6,207 shares of common stock as a compensation award. The grant is in the form of restricted stock units under the company’s 2016 Stock Incentive Plan and will vest in full on June 22, 2027.
The reported transaction is an acquisition by award, not an open-market purchase or sale, and Mr. Bird’s direct holdings after this grant total 6,207 shares according to the filing.
Karran Todd D. reported acquisition or exercise transactions in this Form 4 filing.
AdvanSix Inc. director Karran Todd D. received an equity award of 6,207 shares of common stock as a grant under the company’s 2016 Stock Incentive Plan. The award is in the form of restricted stock units that will vest in full on June 22, 2027.
After this grant, Todd directly holds 91,946 shares of AdvanSix common stock. Because this is a compensation-related award at no purchase price, it reflects standard long-term incentive pay rather than an open-market stock purchase.
Lovett Gena C reported acquisition or exercise transactions in this Form 4 filing.
AdvanSix Inc. reported that director Gena C. Lovett received an equity grant of 6,207 shares of common stock in the form of restricted stock units under the company’s 2016 Stock Incentive Plan. These units will vest in full on June 22, 2027.
Following this award, Lovett directly holds a total of 21,369 AdvanSix shares. Because this is a compensation-related grant at no cash cost to the insider, it represents routine director equity compensation rather than an open-market purchase or sale.
NEWMAN DONALD P reported acquisition or exercise transactions in this Form 4 filing.
AdvanSix Inc. director Donald P. Newman reported receiving a grant of 6,207 restricted stock units of common stock on June 22, 2026. The award was made at no cash price under the 2016 Stock Incentive Plan of AdvanSix Inc. and its Affiliates, as Amended and Restated, and will vest in full on June 22, 2027. Following this compensation grant, Newman directly holds 21,513 shares of AdvanSix common stock.